Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W2RM | ISIN: US00847X1046 | Ticker-Symbol: 8AP
Tradegate
22.04.25
16:45 Uhr
24,000 Euro
-1,200
-4,76 %
1-Jahres-Chart
AGIOS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AGIOS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
25,00025,40016:24
25,00025,20016:24

Aktuelle News zur AGIOS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.03.Agios Pharmaceuticals, Inc.: Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer103CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...
► Artikel lesen
05.03.AGIOS PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
AGIOS Aktie jetzt für 0€ handeln
24.02.H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating3
19.02.Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript2
14.02.Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues2
13.02.Agios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 20255
13.02.Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years2
13.02.AGIOS PHARMACEUTICALS, INC. - 10-K, Annual Report1
13.02.Agios Pharmaceuticals reports Q4 results1
13.02.Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights163- Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union...
► Artikel lesen
13.02.Agios Pharmaceuticals, Inc.: Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint132- ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused - - Safety Results Consistent with Safety Profile for...
► Artikel lesen
13.02.AGIOS PHARMACEUTICALS, INC. - 8-K, Current Report-
12.02.Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb6
12.02.Agios Pharmaceuticals Q4 2024 Earnings Preview2
13.01.Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential2
13.01.AGIOS PHARMACEUTICALS, INC. - 8-K, Current Report-
09.01.FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia25
08.01.Agios' supplemental new drug application for its thalassemia treatment gets FDA nod1
08.01.FDA akzeptiert Agios' sNDA für Thalassämie-Behandlung PYRUKYND6
08.01.FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND1
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1